ERBB2 and neoplasm: In the OlympiA trial, the efficacy of adjuvant olaparib was examined in patients with early-stage HER2-negative tumours and germline BRCA mutations, with high-risk patients defined as those exhibiting a CPS+EG score greater than 3 [21].